Back to results
US 8,076,282 B2Granted
Composition for improving membrane composition and functioning of cells
AssigneeN.V. Nutricia
InventorRobert J. J. Hageman
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeN.V. Nutricia
InventorRobert J. J. Hageman
Estimating the term…
It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a/ a lipid fraction comprising at least one of docosahexanoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b/ a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c/ a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
A method of treating diabetes, obesity or insulin resistance comprising administering a composition including a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction and a protein fraction having a weight ratio of aspartate to glutamate of at least 0.42.
A method for improving the function of a mammalian cell comprising contacting the cell with a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction, and a protein fraction having a weight ratio of aspartate to glutamate of at least 0.42, wherein the mammalian cells are one or more of nerve cells, immune cells, stem cells, bone marrow cells or erythrocytes.
A method for stimulating immune function in a mammal comprising administering a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction, and a protein fraction having a weight ratio of aspartate to glutamate of at least 0.42.
A method for treating obesity in a mammal comprising administering a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction, and a protein fraction having a weight ratio of aspartate to glutamate of at least 0.42.
A method of treating neuropathies, depressed immune function, obesities, diabetes, autoimmune diseases, arrhythmias, heart failures, chronic inflammation and infections caused by diabetes comprising administering a lipid fraction having at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA), a nucleotide fraction, and a protein fraction having a weight ratio of aspartate to glutamate of at least 0.42.
Dependencies are inferred from the claim text.